Navigation Links
Higher risk of birth defects from assisted reproduction
Date:5/5/2012

A University of Adelaide study has identified the risk of major birth defects associated with different types of assisted reproductive technology.

In the most comprehensive study of its kind in the world, researchers from the University's Robinson Institute have compared the risk of major birth defects for each of the reproductive therapies commonly available internationally, such as: IVF (in vitro fertilization), ICSI (intracytoplasmic sperm injection) and ovulation induction. They also compared the risk of birth defects after fresh and frozen embryo transfer.

The results are being published today in the prestigious New England Journal of Medicine, and presented in Barcelona, Spain at the World Congress on Building Consensus in Gynecology, Infertility and Perinatology.

"While assisted reproductive technologies are associated with an increased risk of major birth defects overall, we found significant differences in risk between available treatments," says the lead author of the study, Associate Professor Michael Davies from the University of Adelaide's Robinson Institute and School of Paediatrics and Reproductive Health.

Researchers linked a census of more than 6100 assisted reproductive technology births in South Australia to a registry of more than 300,000 births and 18,000 birth defects. They compared risks of birth defects across all infertility treatments to pregnancies in women with no record of infertility. They also compared successive pregnancies for women.

Previous studies have identified an increased risk of birth defects associated with infertility treatment, but this is the first study to compare all forms of available treatment. This is also the first study to compare pregnancies within women by the treatments received.

AUDIO: Associate professor Michael Davies (Robinson Institute, University of Adelaide) discusses the findings of a study into the risk of major birth defects associated with assisted reproductive technologies.

Click here for more information.

"The unadjusted risk of any birth defect in pregnancies involving assisted conception was 8.3% (513 defects), compared with 5.8% for pregnancies not involving assisted conception (17,546 defects)," Associate Professor Davies says.

"The risk of birth defects for IVF was 7.2% (165 birth defects); and the rate for ICSI was higher at 9.9% (139 defects).

"A history of infertility, either with or without assisted conception, was also significantly associated with birth defects. While factors associated with the causes of infertility explained the excess risk associated with IVF, the increased risk for a number of other treatments could not readily be explained by patient factors. ICSI, for instance, had a 57% increase in the odds of major defect, although the absolute size of the risk remained relatively small," he says.

Associate Professor Davies says cryopreservation (freezing) of embryos was associated with a substantially reduced risk of birth defects, particularly for ICSI. "This may be due to developmentally compromised embryos failing to survive the freeze/thaw process," he says.

Also of concern was the tripling of risk in women using clomiphene citrate to stimulate ovulation outside of a closely supervised clinical setting.

"While confined to a small group in our study, this is of particular concern as clomiphene citrate is now very widely available at low cost, and may easily be used contrary to manufacturers' very specific instructions to avoid use if pregnant, as it may cause fetal malformations. This aspect of the study will need additional confirmation from future research," Associate Professor Davies says.

He says the study now needs to be expanded to include more recent years of treatment, as the reproductive technologies have undergone continual innovation which may influence the associated risks of treatment.


'/>"/>

Contact: Michael Davies
michael.davies@adelaide.edu.au
University of Adelaide
Source:Eurekalert

Related biology news :

1. Obese patients face higher radiation exposure from CT scans -- but new technology can help
2. Cirrhotic patients experience increased daytime sleepiness from higher ammonia levels
3. Higher risk of autism among certain immigrant groups
4. Study finds Caribbean-American women at higher risk for elevated mercury levels
5. Diabetes risk factors in young Sri Lankans much higher than previously thought
6. Asthma rate and costs from traffic-related air pollution are much higher than once believed
7. Salt-tolerant crops show higher capacity for carbon fixation
8. Climate change driving tropical birds to higher elevations
9. New, higher estimates of endangered humpback whales in the North Pacific
10. The risk of suffering from insomnia is 67 percent higher if a family member is insomniac
11. Differences in cell response could explain higher rates of hypertension in African-Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... 2016  Silk Therapeutics, Inc., today announced the closing of ... now raised a total of $10.25 million in Series A ... Series A2 round was led by existing investor The Kraft ... from new investors Lear Corporation and Highland Consumer Partners, as ... ; Richard Sackler , MD, with Summer Road, LLC; ...
Breaking Biology Technology: